Vistin Pharma ASA (LTS:0RAM) Cash Flow from Investing: kr-17.2 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RAM Vistin Pharma ASA LTS:0RAM
75 GF Score
Price kr20.30
GF Value kr25.92
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Cash Flow from Investing?

Vistin Pharma ASA LTS:0RAM 75 Cash Flow from Investing is kr-17.2 Mil as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 75/100 and a GF Value™ of kr25.92 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2026, Vistin Pharma ASA spent kr5.9 Mil on purchasing property, plant, equipment. It gained kr0.0 Mil from selling property, plant, and equipment. It spent kr0.0 Mil on purchasing business. It gained kr0.0 Mil from selling business. It spent kr0.0 Mil on purchasing investments. It gained kr0.0 Mil from selling investments. It paid kr0.0Mil for net Intangibles purchase and sale. And it paid kr0.0 Mil for other investing activities. In all, Vistin Pharma ASA spent kr5.9 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2026.


Vistin Pharma ASA  (LTS:0RAM) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Vistin Pharma ASA's purchase of property, plant, equipment for the three months ended in Mar. 2026 was kr-5.9 Mil. It means Vistin Pharma ASA spent kr5.9 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Vistin Pharma ASA's sale of property, plant, equipment for the three months ended in Mar. 2026 was kr0.0 Mil. It means Vistin Pharma ASA gained kr0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Vistin Pharma ASA's purchase of business for the three months ended in Mar. 2026 was kr0.0 Mil. It means Vistin Pharma ASA spent kr0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Vistin Pharma ASA's sale of business for the three months ended in Mar. 2026 was kr0.0 Mil. It means Vistin Pharma ASA gained kr0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Vistin Pharma ASA's purchase of investment for the three months ended in Mar. 2026 was kr0.0 Mil. It means Vistin Pharma ASA spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Vistin Pharma ASA's sale of investment for the three months ended in Mar. 2026 was kr0.0 Mil. It means Vistin Pharma ASA gained kr0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Vistin Pharma ASA's net Intangibles purchase and sale for the three months ended in Mar. 2026 was kr0.0 Mil. It means Vistin Pharma ASA paid kr0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Vistin Pharma ASA's cash from discontinued investing activities for the three months ended in Mar. 2026 was 0.0 Mil. It means Vistin Pharma ASA paid kr0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Vistin Pharma ASA's cash from other investing activities for the three months ended in Mar. 2026 was kr0.0 Mil. It means Vistin Pharma ASA paid kr0.0 Mil for other investing activities.


Vistin Pharma ASA Cash Flow from Investing Related Terms


Vistin Pharma ASA Cash Flow from Investing Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Cash Flow from Investing Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -31.68 -64.26 -17.68 -40.30 -16.29

Vistin Pharma ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.03 -3.43 -1.71 -6.11 -5.91
LTS:0RAM
75GF Score
Vistin Pharma ASA LTS:0RAM
Cash Flow from Investing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Vistin Pharma ASA's Cash Flow from Investing for the fiscal year that ended in Dec. 2025 is calculated as:

Vistin Pharma ASA's Cash Flow from Investing for the quarter that ended in Mar. 2026 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-17.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Investing of kr-17.2 Mil mean?
Vistin Pharma ASA (LTS:0RAM) has a Cash Flow from Investing of kr-17.2 Mil as of Mar. 2026. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Vistin Pharma ASA and its competitors.
Is Vistin Pharma ASA's Cash Flow from Investing too high?
Vistin Pharma ASA's current Cash Flow from Investing is kr-17.2 Mil. Overall, Vistin Pharma ASA has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Cash Flow from Investing compare to ZTS and UTHR?
Vistin Pharma ASA's Cash Flow from Investing of kr-17.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Drug Manufacturers company?
A good Cash Flow from Investing depends on the Drug Manufacturers industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Vistin Pharma ASA and its competitors. Vistin Pharma ASA's current Cash Flow from Investing is kr-17.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.92, compared to a current price of kr20.30 — trading 21.7% below its estimated fair value. The current Cash Flow from Investing is kr-17.2 Mil. Vistin Pharma ASA's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Cash Flow from Investing is kr-17.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr20.30 is trading 21.7% below its estimated GF Value™ of kr25.92. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Cash Flow from Investing: kr-17.2 Mil
  • GF Value™: kr25.92 vs. price of kr20.30 (21.7% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
75GF Score

Get the complete analysis for LTS:0RAM

Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.30
Price
kr25.92
GF Value